FDD review · reviewed July 29, 2026
| Franchise fee | ~$49,500 |
|---|---|
| All-in investment (Item 7) | ~$224,000–$410,000 |
| Ongoing take (Item 6) | 6% royalty on gross + ~$2,000/mo local advertising |
| Franchised units | 257 in 37 states (2025 FDD) |
| Model | Prescription men's health: TRT, GLP-1 weight loss; semi-absentee positioning |
GameDay is the fastest-scaling franchise in the men's-health/metabolic lane: 257 franchised US locations across 37 states per the 2025 FDD, with the consumer site claiming "400+ clinics across the US & Canada." Franchise portals report over 1,000 licenses sold. That growth is genuine — and it is also where the sharpest diligence question lives (below).
The headline performance figures widely quoted for this brand — roughly $1.89M average gross revenue and $627K average adjusted earnings — trace to an early cohort of units. Analyses of the more recent FDD data show materially lower figures for the broader system: on the order of $761K average gross and $114K–$152K owner earnings. Both sets of numbers can be simultaneously true; they describe different units in different years. Before relying on either, ask the franchisor which FDD year and which cohort each figure comes from, and what the median unit shows in the current Item 19.
Portals report 1,000+ licenses sold and 300+ locations awarded in a single year, against roughly 260 open units in the 2025 FDD. A gap between licenses sold and doors open is not unusual in fast-selling systems — but the size of the gap is a data point worth asking about directly: how many of the licenses sold in the last 24 months have opened?
6% of gross plus a monthly local-advertising obligation, for the life of the agreement, on a brand the franchisee does not own. Run it at your own projected volume over ten years before comparing entry fees — the entry fee is the headline, the ongoing take is the business model.
This is a prescription-medicine model (testosterone replacement, GLP-1 weight loss), which means per-clinic medical oversight and prescribing compliance at every location. The company also currently faces a pending class action relating to website tracking pixels; as with any pending matter, no outcome should be assumed.